“…Data further suggest that NAF can potentially be used for LUTS/BPH and PCa treatment and prevention. However, because of its low bioavailability (9% in rats and 18% in human), the clinical medication dose of racemic NAF is as high as 25-75 mg/kg, which is more than that of other BPH therapeutic drugs (e.g., 0.2 mg/day tamsulosin, 1-5 mg/day terazosin, and 5 mg finasteride) [10]. For this reason, we sought to investigate the pharmacokinetics of NAF in this study.…”